788 related articles for article (PubMed ID: 23877261)
21. Efficacy of rapamycin against glioblastoma cancer stem cells.
Mendiburu-Eliçabe M; Gil-Ranedo J; Izquierdo M
Clin Transl Oncol; 2014 May; 16(5):495-502. PubMed ID: 24043497
[TBL] [Abstract][Full Text] [Related]
22. Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
Oppermann H; Faust H; Yamanishi U; Meixensberger J; Gaunitz F
PLoS One; 2019; 14(6):e0218972. PubMed ID: 31247000
[TBL] [Abstract][Full Text] [Related]
23. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
[TBL] [Abstract][Full Text] [Related]
24. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells.
Martelli AM; Evangelisti C; Follo MY; Ramazzotti G; Fini M; Giardino R; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2011; 18(18):2715-26. PubMed ID: 21649579
[TBL] [Abstract][Full Text] [Related]
25. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity.
Sunayama J; Sato A; Matsuda K; Tachibana K; Watanabe E; Seino S; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2011 Sep; 29(9):1327-37. PubMed ID: 21793107
[TBL] [Abstract][Full Text] [Related]
26. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
Ramakrishnan V; Kimlinger T; Haug J; Painuly U; Wellik L; Halling T; Rajkumar SV; Kumar S
PLoS One; 2012; 7(11):e50005. PubMed ID: 23185517
[TBL] [Abstract][Full Text] [Related]
27. mTOR inhibitor temsirolimus and MEK1/2 inhibitor U0126 promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells.
Stepanenko AA; Andreieva SV; Korets KV; Mykytenko DO; Baklaushev VP; Chekhonin VP; Dmitrenko VV
Gene; 2016 Mar; 579(1):58-68. PubMed ID: 26748241
[TBL] [Abstract][Full Text] [Related]
28. Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells.
Mise J; Dembitz V; Banfic H; Visnjic D
Pathol Oncol Res; 2011 Sep; 17(3):645-56. PubMed ID: 21336564
[TBL] [Abstract][Full Text] [Related]
29. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Daniele S; Zappelli E; Natali L; Martini C; Trincavelli ML
Cell Death Dis; 2014 Nov; 5(11):e1539. PubMed ID: 25429616
[TBL] [Abstract][Full Text] [Related]
30. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
31. All-trans retinoic acid impairs the vasculogenic mimicry formation ability of U87 stem-like cells through promoting differentiation.
Ling GQ; Liu YJ; Ke YQ; Chen L; Jiang XD; Jiang CL; Ye W
Mol Med Rep; 2015 Jul; 12(1):165-72. PubMed ID: 25760394
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Gery S; Koeffler HP; Yokoyama A
Int J Cancer; 2009 Oct; 125(7):1710-20. PubMed ID: 19507250
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
[TBL] [Abstract][Full Text] [Related]
34. Role of mTOR in glioblastoma.
Duzgun Z; Eroglu Z; Biray Avci C
Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051
[TBL] [Abstract][Full Text] [Related]
35. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
[TBL] [Abstract][Full Text] [Related]
36. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
Dormond-Meuwly A; Roulin D; Dufour M; Benoit M; Demartines N; Dormond O
Biochem Biophys Res Commun; 2011 Apr; 407(4):714-9. PubMed ID: 21439267
[TBL] [Abstract][Full Text] [Related]
37. Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling.
Chandrika G; Natesh K; Ranade D; Chugh A; Shastry P
Sci Rep; 2016 Mar; 6():22455. PubMed ID: 26940200
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma.
Yang C; Zhang Y; Zhang Y; Zhang Z; Peng J; Li Z; Han L; You Q; Chen X; Rao X; Zhu Y; Liao Z
Int J Oncol; 2015 Sep; 47(3):909-17. PubMed ID: 26202311
[TBL] [Abstract][Full Text] [Related]
39. Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients.
Chow S; Minden MD; Hedley DW
Exp Hematol; 2006 Sep; 34(9):1183-91. PubMed ID: 16939811
[TBL] [Abstract][Full Text] [Related]
40. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
